
- /
- Supported exchanges
- / BR
- / BIOS.BR
BioSenic S.A. (BIOS BR) stock market data APIs
BioSenic S.A. Financial Data Overview
BioSenic S.A., a biotechnology company, develops cell therapy products and treatments for autoimmune and inflammatory diseases in Belgium and France. The company's technologies include arsenic trioxide (ATO) and oral arsenic trioxide (OATO) platforms. It also provides medicinal products, including ArsciMed, an intravenous drug to treat autoimmune diseases. In addition, the company develops ArsciCor, an oral medication in Phase III clinical trial and for the treatment for chronic graft-versus-host disease; JTA-004, an intra-articular injectable in Phase III clinical trial to treat osteoarthritic knee pain; ALLOB, an allogeneic differentiated osteoblast product in Phase IIb clinical trial for patients with difficult tibial fractures and lumbar spinal fusion; and ARSCICOP, an oral medication in Phase IIa trial for the treatment of systemic lupus erythematosus, as well as in preclinical trial to treat systemic sclerosis. BioSenic S.A. is based in Mont-Saint-Guibert, Belgium.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get BioSenic S.A. data using free add-ons & libraries
Get BioSenic S.A. Fundamental Data
BioSenic S.A. Fundamental data includes:
- Net Revenue: 2 665 K
- EBITDA: -3 559 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2024-09-29
- EPS/Forecast: 0
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
BioSenic S.A. News

BioSenic provides third quarter 2023 Business Update
REGULATED INFORMATION Following the in-principle agreement reached with its main creditors in the context of ongoing equity raise process, the focus of BioSenic is now to proceed with fundraising, al...


BioSenic to draw the final tranches of its present Global Tech Opportunities 15 convertible bonds program and secure runway end of January 2024
INSIDE INFORMATION Mont-Saint-Guibert, Belgium, October 18, 2023, 7.00am CEST – BioSenic to draw the final tranches of its present Global Tech Opportunities 15 convertible bonds program and secure...

Correction: BioSenic S.A. : Transparency notifications received from François Rieger, Véronique Pomi, FA Dièse 3 SAS and Capital Grand Est SAS
REGULATED INFORMATION This is a corrected version of the original PR "Transparency notifications received from François Rieger, Véronique Pomi, FA Dièse 3 SAS and Capital Grand Est SAS" published ...

BioSenic S.A. : Transparency notifications received from François Rieger, Véronique Pomi, FA Dièse 3 SAS and Capital Grand Est SAS
REGULATED INFORMATION Article 14 of the Law of 2 May 2007 on disclosure of major holdings Mont-Saint-Guibert, Belgium, October 17, 2022, 7am CEST – Transparency notifications received from Franç...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.